非小细胞肺癌患者获得性耐药后重新使用 EGFR-TKIs 治疗。
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance.
机构信息
Department of Chest Medicine, Taipei Veteran General Hospital, Yang-Min National University, No. 21, Sec. 2, Shi-Pai Rd., Taipei 11217, Taiwan.
出版信息
J Pers Med. 2014 Jun 25;4(3):297-310. doi: 10.3390/jpm4030297.
Abstract
In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threonine at position 790 (T790M), which has accounted for more than half of the cases, developed inevitably in patients who were previously treated with EGFR-TKI. At present, there is no standard treatment for patients who have developed a resistance to EGFR-TKI. Several strategies have been developed or suggested to treat such patients. This article aimsto review the EGFR-TKI re-treatment strategy and the efficacy of different generations of EGFR-TKIs in patients with acquired resistance to prior EGFR-TKI.
摘要
在个性化医学时代，表皮生长因子受体（EGFR）抑制剂与酪氨酸激酶抑制剂（TKI）的联合治疗已经成为 EGFR 突变的非小细胞肺癌（NSCLC）患者的主要治疗方法。获得性耐药，尤其是第 790 位苏氨酸被蛋氨酸取代（T790M），已成为先前接受 EGFR-TKI 治疗的患者不可避免的问题，其占比超过一半。目前，对于 EGFR-TKI 耐药的患者，还没有标准的治疗方法。已经开发或提出了几种策略来治疗此类患者。本文旨在综述 EGFR-TKI 再治疗策略以及不同代 EGFR-TKIs 在 EGFR-TKI 获得性耐药患者中的疗效。
相似文献
1
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance.
J Pers Med. 2014 Jun 25;4(3):297-310. doi: 10.3390/jpm4030297.
2
Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
Antioxid Redox Signal. 2016 Feb 10;24(5):263-79. doi: 10.1089/ars.2015.6420. Epub 2015 Dec 14.
3
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.
Transl Lung Cancer Res. 2014 Dec;3(6):370-2. doi: 10.3978/j.issn.2218-6751.2014.08.02.
4
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.
5
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Onco Targets Ther. 2016 Sep 6;9:5461-73. doi: 10.2147/OTT.S94745. eCollection 2016.
6
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lung Cancer. 2017 Nov;113:106-114. doi: 10.1016/j.lungcan.2017.09.005. Epub 2017 Sep 12.
7
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Oncotarget. 2016 Aug 9;7(32):51311-51319. doi: 10.18632/oncotarget.9697.
8
Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Ann Transl Med. 2018 Apr;6(8):140. doi: 10.21037/atm.2017.10.04.
9
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
BMC Cancer. 2016 Nov 8;16(1):864. doi: 10.1186/s12885-016-2902-0.
10
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
引用本文的文献
1
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.
Int J Mol Sci. 2022 Jun 24;23(13):7037. doi: 10.3390/ijms23137037.
2
Multifunctional neuron-specific enolase: its role in lung diseases.
Biosci Rep. 2019 Nov 29;39(11). doi: 10.1042/BSR20192732.
3
Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.
Cancer Med. 2019 May;8(5):1976-1995. doi: 10.1002/cam4.2112. Epub 2019 Apr 17.
4
Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Oncotarget. 2017 Jul 20;8(65):108522-108533. doi: 10.18632/oncotarget.19411. eCollection 2017 Dec 12.
5
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Clin Drug Investig. 2018 Apr;38(4):319-331. doi: 10.1007/s40261-017-0611-3.
6
Activation of Epidermal Growth Factor Receptor/p38/Hypoxia-inducible Factor-1α Is Pivotal for Angiogenesis and Tumorigenesis of Malignantly Transformed Cells Induced by Hexavalent Chromium.
J Biol Chem. 2016 Jul 29;291(31):16271-81. doi: 10.1074/jbc.M116.715797. Epub 2016 May 25.
7
Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Dis Markers. 2016;2016:3823121. doi: 10.1155/2016/3823121. Epub 2016 Jan 11.
8
Value of serum marker HE4 in pulmonary carcinoma diagnosis.
Int J Clin Exp Med. 2015 Oct 15;8(10):19014-21. eCollection 2015.
9
Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer.
Int J Clin Exp Med. 2015 Jun 15;8(6):9498-504. eCollection 2015.
10
Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance.
Int J Clin Exp Med. 2015 Apr 15;8(4):5397-405. eCollection 2015.
本文引用的文献
1
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer. 2014 Apr 15;120(8):1145-54. doi: 10.1002/cncr.28561. Epub 2014 Feb 5.
2
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15.
3
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
J Thorac Oncol. 2014 Feb;9(2):154-62. doi: 10.1097/JTO.0000000000000033.
4
EGFR mutations in lung cancer: different frequencies for different folks.
J Thorac Oncol. 2014 Feb;9(2):139-40. doi: 10.1097/JTO.0000000000000063.
5
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.
BMC Cancer. 2013 Dec 27;13:606. doi: 10.1186/1471-2407-13-606.
6
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.
Clin Lung Cancer. 2014 Jan;15(1):1-6. doi: 10.1016/j.cllc.2013.10.001. Epub 2013 Oct 12.
7
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
Oncologist. 2013;18(11):1214-20. doi: 10.1634/theoncologist.2013-0168. Epub 2013 Sep 26.
8
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.
9
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
J Clin Oncol. 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. Epub 2013 Jul 1.
10
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
Zotero 插件